Your browser doesn't support javascript.
loading
The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence.
Capizzi, Antonino; Silvestri, Michela; Orsi, Andrea; Cutrera, Renato; Rossi, Giovanni A; Sacco, Oliviero.
Afiliação
  • Capizzi A; Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy.
  • Silvestri M; Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy.
  • Orsi A; Department of Health Sciences, Hygiene Unit, IRCCS University Hospital San Martino Polyclinic, Genoa, Italy.
  • Cutrera R; Pediatric Pulmonology and Sleep & Long Term Ventilation Unit, Pediatric Hospital "Bambino Gesù", Rome, Italy. renato.cutrera@opbg.net.
  • Rossi GA; Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy.
  • Sacco O; Department of Pediatrics, Pulmonology and Allergy Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy.
Ital J Pediatr ; 43(1): 71, 2017 Aug 14.
Article em En | MEDLINE | ID: mdl-28807039
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Recém-Nascido Prematuro / Bronquiolite / Infecções por Vírus Respiratório Sincicial / Palivizumab Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Recém-Nascido Prematuro / Bronquiolite / Infecções por Vírus Respiratório Sincicial / Palivizumab Idioma: En Ano de publicação: 2017 Tipo de documento: Article